Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:CARM

Carisma Therapeutics 8/21/2026 Earnings Report

Carisma Therapeutics logo
$0.0012 0.00 (-47.83%)
As of 02:10 PM Eastern
ProfileEarnings HistoryForecast

Carisma Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.11
Beat/Miss
N/A
One Year Ago EPS
N/A

Carisma Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$4.23 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Carisma Therapeutics Announcement Details

Quarter
Date
8/21/2026
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Carisma Therapeutics Earnings Headlines

Carisma Therapeutics (CARM) to Post Earnings on Monday
August 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30963301
Carmila: 2025 Annual Results
February 18, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260218091340/en/Carmila-2025-Annual-Results/
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
August 21 at 1:00 AM  |  Chaikin Analytics (Ad)
Carisma Therapeutics announces Nasdaq delisting, SEC deregistration
December 6, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/carisma-therapeutics-announces-nasdaq-delisting-sec-deregistration/ar-AA1RNAg1
Carisma Announces Delisting from Nasdaq and SEC Deregistration
December 5, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/carisma-announces-delisting-from-nasdaq-and-sec-deregistration-302634179.html
Carisma Therapeutics Announces Executive Terminations and Wind-Down
October 17, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/carisma-therapeutics-announces-executive-terminations-and-wind-down/ar-AA1Oy1kT
See More Carisma Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Carisma Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Carisma Therapeutics and other key companies, straight to your email.

About Carisma Therapeutics

Carisma Therapeutics (NASDAQ:CARM), Inc. is a clinical-stage biotechnology company headquartered in the United States that focuses on harnessing the innate immune system to treat cancer and inflammatory diseases. Through its proprietary CARMA (Chimeric Antigen Receptor Macrophage) platform, Carisma engineers macrophages and other myeloid cells to seek out, engulf and destroy diseased cells while reprogramming the surrounding microenvironment. This approach aims to address key limitations of existing T-cell therapies by leveraging the unique trafficking and immunomodulatory properties of innate immune cells.

The company’s lead oncology candidate, CT-0508, employs a HER2-targeted CAR expressed on macrophages to infiltrate and remodel HER2-positive solid tumors. In parallel, Carisma is advancing CT-381, an engineered myeloid cell therapy designed to modulate inflammatory and autoimmune conditions. Preclinical data have demonstrated robust antigen-dependent activation, tumor penetration and anti-tumor efficacy in multiple models, supporting the progression of these programs toward their first clinical studies.

Carisma’s interdisciplinary team combines expertise in myeloid biology, genetic engineering and translational medicine. The company partners with leading academic institutions and specialized contract development and manufacturing organizations to establish scalable, GMP-compliant processes for its cell therapies. By uniting macrophage biology with CAR engineering, Carisma Therapeutics seeks to create a novel class of treatments with broad applications across oncology and immune-mediated diseases.

View Carisma Therapeutics Profile
Earnings Tools